Search for a trial

Neoadjuvant nivolumab combination treatment in resectable non-small cell lung cancer patients: Defining optimal combinations and determinants of immunological response

This study has been transitioned to CTIS with ID 2024-513074-22-00 check the CTIS register for the current data. Primary Objective:The primary objective of this study is to determine the feasibility of four weeks of preoperative immunotherapy with…

A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of
Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants with Recurrent or
Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma

This study has been transitioned to CTIS with ID 2023-503715-14-00 check the CTIS register for the current data. Part A: To characterize the safety, tolerability, and define the MTD or RP2D for the combination of relatlimab + nivolumab in pediatric…

Neoadjuvant immune checkpoint inhibition and novel IO combinations in early-stage colon cancer. The NICHE trial.

This study has been transitioned to CTIS with ID 2024-513314-35-00 check the CTIS register for the current data. Primary Objective: To determine the safety and feasibility of pre-operative immunotherapy in CRC. Additional Primary Objective for the…

Pre-operative phase II trial for breast cancer with nivolumab in combination with novel IO (BELLINI trial)

This study has been transitioned to CTIS with ID 2024-515080-54-00 check the CTIS register for the current data. Primary objectiveTo determine the pathological complete response rate per cohort